Solaris Biotechnology, a designer and manufacturer of bioprocessing equipment, was acquired by Donaldson Co. Inc., a leading worldwide provider of innovative filtration products and solutions, according to a Donaldson Co. release.
Solaris is an attractive acquisition, given its equipment includes bioreactors, fermenters and tangential flow filtration systems for use in food and beverage, biotechnology and other life sciences markets. The company’s product portfolio ranges from benchtop systems for research and development to pilot and commercial-scale manufacturing systems.
“By being part of Donaldson, we will have the global scale and financial flexibility to continue delivering on our growth plans, and we are thrilled about this opportunity,” Matteo Brognoli, co-founder and chief executive officer of Solaris, said in a statement. “Like Donaldson, Solaris is built on strong customer relationships and providing technologically advanced solutions. With the need for Solaris products expanding rapidly we are better able to meet the growing need while playing an important role in Donaldson’s expansion into life sciences.”
Founded in 2002, Solaris has about 30 employees and is headquartered in Porto Mantovano, Italy, with U.S. operations based in Berkeley, Calif. Donaldson acquired Solaris for approximately $46.4 million.
“We are excited about Solaris’ capabilities and growth trajectory, and this acquisition is an important step on our journey towards strengthening our presence in the life sciences market,” Tod Carpenter, chairman, president and chief executive officer of Donaldson, said in a release. “With Solaris, we are well-positioned to provide more comprehensive solutions to food and beverage customers and expand our access to biopharma and other key life sciences markets.”